Výsledky vyhledávání - "Russell Zelig Szmulewitz"

FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)

Publikováno v: Journal of Clinical Oncology. 41:303-303

303 Background: Six months of a GnRH agonist with SRT is a standard of care for patients with unfavorable features and a detectable PSA post-RP. FORMULA-509 was designed to evaluate whether adding six months of AAP and Apa to this regimen could impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a605870d72cae7a74cee2e293b548ce9
https://doi.org/10.1200/jco.2023.41.6_suppl.303

Zobrazit plný text záznamu

Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES

Autor: Andrew J. Armstrong, Nicolas Mottet, Taro Iguchi, Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Ho-Jin Lee, Gabriel P. Haas, Arnulf Stenzl, Arun Azad

Publikováno v: Journal of Clinical Oncology. 40:5072-5072

5072 Background: Enzalutamide (ENZA) + androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression and increased overall survival in men with mHSPC, regardless of baseline PSA levels (ARCHES; NCT02677896). This post

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b497bed59d2f988211b7a39b2dcc80bb
https://doi.org/10.1200/jco.2022.40.16_suppl.5072

Zobrazit plný text záznamu

Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis

Autor: Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arun Azad, Taro Iguchi, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Brad Rosbrook, Fabian Zohren, Jie Ma, Gabriel P. Haas, Francisco Gomez-Veiga, Arnulf Stenzl, Andrew J. Armstrong

Publikováno v: Journal of Clinical Oncology. 40:5069-5069

5069 Background: Patients with metastatic prostate cancer aged ≥75 years have a poorer prognosis compared with younger patients. In ARCHES (NCT02677896), ENZA + ADT improved radiographic progression-free survival (rPFS), overall survival (OS), and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c156687f95b6232a7e5c81fa1e1b5ca
https://doi.org/10.1200/jco.2022.40.16_suppl.5069

Zobrazit plný text záznamu

BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects

Autor: Maha H. A. Hussain, Masha Kocherginsky, Neeraj Agarwal, Jingsong Zhang, Nabil Adra, Channing Judith Paller, Joel Picus, Zachery R Reichert, Russell Zelig Szmulewitz, Scott T. Tagawa, Young E. Whang, Robert Dreicer, Timothy Kuzel, Latifa Bazzi, Travis A. Gerke, Stephanie Daignault-Newton, Arul Chinnaiyan, Emmanuel S. Antonarakis

Publikováno v: Journal of Clinical Oncology. 40:5018-5018

5018 Background: The PARP-inhibitor olaparib is approved for mCRPC patients (pts) with deleterious germline or somatic homologous recombination repair gene mutations (HRRm). PARP1 interacts with androgen signaling, and castration-resistant tumor cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5785229f9d38660267fd65bee72161c
https://doi.org/10.1200/jco.2022.40.16_suppl.5018

Zobrazit plný text záznamu

A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE)

Autor: Alicia K. Morgans, Yu-Hui Chen, Anna C. C. Ferrari, Phuoc T. Tran, Edward M. Schaeffer, Daniel H. Shevrin, Russell Zelig Szmulewitz, Thomas Boike, Tanya B. Dorff, Glenn Liu, Lynne I. Wagner, Michael Anthony Carducci

Publikováno v: Journal of Clinical Oncology. 40:TPS5114-TPS5114

TPS5114 Background: Patients with high-risk scores by Decipher molecular testing after prostatectomy have a 5-year metastasis rate of 28% (Decipher 0.6-0.7) and 38% (Decipher > 0.7), likely due to micrometastatic disease. Clinical trials with intensi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1752c7b4a1afa98f11ca24b3065cb7ec
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5114

Zobrazit plný text záznamu

Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial

Autor: Andrew J. Armstrong, Taro Iguchi, Arun Azad, Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alexeev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl

Publikováno v: Journal of Clinical Oncology. 40:115-115

115 Background: In ARCHES (NCT02677896), ENZA + ADT improved radiographic progression-free survival, OS, and other key secondary endpoints vs placebo (PBO) + ADT for pts with mHSPC (also known as metastatic castration-sensitive prostate cancer). Fina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d2bcb883649b8709bdfc35c88c68a18
https://doi.org/10.1200/jco.2022.40.6_suppl.115

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání